{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:53:15Z","timestamp":1781823195615,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Dry eye disease (DED) is a multifactorial ocular surface disorder characterized by loss of tear film homeostasis, inflammation, neurosensory abnormalities, and epithelial damage. Despite the availability of topical immunomodulators and procedural interventions, a substantial proportion of patients with moderate-to-severe or refractory DED experience persistent symptoms and inadequate ocular surface recovery. Stem cell\u2013based therapies, particularly mesenchymal stem cells (MSCs) and MSC-derived exosomes, have emerged as regenerative and immunomodulatory strategies aimed at restoring epithelial integrity and tear film stability rather than providing solely symptomatic relief. We conducted a systematic review and meta-analysis to evaluate the clinical efficacy and safety of stem cell and stem cell\u2013derived therapies in human DED.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study followed PRISMA 2020 guidelines and was prospectively registered in PROSPERO (CRD420251057372). Six databases were searched from inception to May 14, 2025. Eligible studies were peer-reviewed human clinical investigations evaluating stem cell\u2013based interventions for DED and reporting objective efficacy outcomes such as Schirmer test, tear break-up time (TBUT), corneal fluorescein staining (CFS), or patient-reported outcomes including the Ocular Surface Disease Index (OSDI). Pooled mean differences (MDs) or standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated. Statistical heterogeneity was assessed using the I\u00b2 statistic. Risk of bias was evaluated using RoB 2 for randomized controlled trials and ROBINS-I for non-randomized studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six studies comprising 131 patients were included. Stem cell\u2013based therapies demonstrated significant improvements in tear production, tear film stability, epithelial integrity, and symptom burden. Schirmer test improved by MD = 4.70 mm (95% CI, 4.18\u20135.22;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001; I\u00b2 = 12.59%), indicating a consistent enhancement of aqueous tear secretion. TBUT showed a large standardized improvement with pooled SMD = 1.125 (95% CI, 0.821\u20131.428; p &lt; 0.001), although randomized trials demonstrated smaller effect sizes than non-randomized studies. OSDI scores decreased by MD = \u221211.44 points (95% CI, \u221222.71 to \u22120.17;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.047), reflecting symptomatic improvement but with substantial between-study variability. Corneal fluorescein staining decreased by MD = \u22121.04 (95% CI, \u22121.23 to \u22120.84;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001; I\u00b2 = 0%), supporting epithelial recovery. No serious treatment-related adverse events were reported; however, safety reporting was heterogeneous and follow-up durations were limited.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Stem cell and stem cell\u2013derived therapies are associated with significant improvements in both objective and subjective outcomes in DED and demonstrate a favorable short-term safety profile. Nevertheless, heterogeneity in cell source, delivery route, dosage, and study design limits generalizability. Larger, rigorously designed randomized trials with standardized protocols and longer follow-up are required to confirm efficacy and establish long-term safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-026-04915-8","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:14:13Z","timestamp":1777623253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of stem cell therapy for dry eye disease: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"17","author":[{"given":"Kai-Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Chun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ming","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"11","key":"4915_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112264","volume":"18","author":"AJ Villatoro","year":"2017","unstructured":"Villatoro AJ, et al. Regenerative therapies in dry eye disease: from growth factors to cell therapy. Int J Mol Sci. 2017;18(11):2264.","journal-title":"Int J Mol Sci"},{"key":"4915_CR2","volume-title":"StatPearls","author":"MI Golden","year":"2024","unstructured":"Golden MI, Meyer JJ, Zeppieri M, Patel BC. Dry eye syndrome. In: StatPearls. Tampa: StatPearls Publishing; 2024."},{"issue":"2","key":"4915_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4103\/1319-4534.337849","volume":"35","author":"ZA Hasan","year":"2021","unstructured":"Hasan ZA. Dry eye syndrome risk factors: a systemic review. Saudi J Ophthalmol. 2021;35(2):131\u20139.","journal-title":"Saudi J Ophthalmol"},{"issue":"10","key":"4915_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2025.109149","volume":"39","author":"KY Chen","year":"2025","unstructured":"Chen KY, Chan HC, Chan CM. Is there a link between dry eye disease and diabetes mellitus? A systematic review and meta-analysis. J Diabetes Complications. 2025;39(10):109149. https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109149.","journal-title":"J Diabetes Complications"},{"issue":"5","key":"4915_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2025.102438","volume":"48","author":"KY Chen","year":"2025","unstructured":"Chen KY, Chan HC, Chan CM. How effective and safe are punctal plugs in treating dry eye disease? A systematic review and meta-analysis. Contact Lens Anterior Eye. 2025;48(5):102438. https:\/\/doi.org\/10.1016\/j.clae.2025.102438.","journal-title":"Contact Lens Anterior Eye"},{"key":"4915_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04454-8","author":"KY Chen","year":"2025","unstructured":"Chen KY, Chan HC, Chan CM. Which topical ophthalmic drugs work best for Keratoconjunctivitis Sicca? A systematic review and meta-analysis. Naunyn Schmiedebergs Arch Pharmacol Jul. 2025. https:\/\/doi.org\/10.1007\/s00210-025-04454-8.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol Jul"},{"key":"4915_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/25158414251338775","volume":"17","author":"KY Chen","year":"2025","unstructured":"Chen KY, Chan HC, Chan CM. Is a thermal pulsation system (LipiFlow) effective as a standalone treatment for meibomian gland dysfunction and dry eye? A systematic review and meta-analysis. Ther Adv Ophthalmol. 2025;17:25158414251338775. https:\/\/doi.org\/10.1177\/25158414251338775.","journal-title":"Ther Adv Ophthalmol"},{"key":"4915_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2025.104630","volume":"53","author":"KY Chen","year":"2025","unstructured":"Chen KY, Chan HC, Chan CM. Which treatment works better for meibomian gland dysfunction: LipiFlow or intense pulsed light? A systematic review and network meta-analysis. Photodiagnosis Photodyn Ther. 2025;53:104630. https:\/\/doi.org\/10.1016\/j.pdpdt.2025.104630.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"8","key":"4915_CR9","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/s41433-025-03790-6","volume":"39","author":"KY Chen","year":"2025","unstructured":"Chen KY, Chan HC, Chan CM. Is botulinum toxin A effective in treating dry eye disease? A systematic review and meta-analysis. Eye (Lond). 2025;39(8):1457\u201364. https:\/\/doi.org\/10.1038\/s41433-025-03790-6.","journal-title":"Eye (Lond)"},{"issue":"1","key":"4915_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/07853890.2022.2157477","volume":"55","author":"J Sheppard","year":"2023","unstructured":"Sheppard J, Shen Lee B, Periman LM. Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists. Ann Med. 2023;55(1):241\u201352. https:\/\/doi.org\/10.1080\/07853890.2022.2157477.","journal-title":"Ann Med"},{"issue":"5","key":"4915_CR11","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1007\/s12015-025-10884-x","volume":"21","author":"KY Chen","year":"2025","unstructured":"Chen KY, Chan HC, Chan CM. Can stem cell therapy revolutionize ocular disease treatment? A critical review of preclinical and clinical advances. Stem Cell Rev Rep. 2025;21(5):1160\u201385. https:\/\/doi.org\/10.1007\/s12015-025-10884-x.","journal-title":"Stem Cell Rev Rep"},{"issue":"12","key":"4915_CR12","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s40265-025-02237-2","volume":"85","author":"KY Chen","year":"2025","unstructured":"Chen KY, Chan HC, Chan CM. Can gene therapy transform the treatment landscape of posterior segment eye diseases? A comprehensive review of recent advancements. Drugs. 2025;85(12):1585\u2013608. https:\/\/doi.org\/10.1007\/s40265-025-02237-2.","journal-title":"Drugs"},{"issue":"1","key":"4915_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13036-025-00548-2","volume":"19","author":"KY Chen","year":"2025","unstructured":"Chen KY, Chan HC, Chan CM. Can bionic eyes restore vision? Breakthroughs, challenges, and future frontiers in ophthalmology - a comprehensive review. J Biol Eng. 2025;19(1):106. https:\/\/doi.org\/10.1186\/s13036-025-00548-2.","journal-title":"J Biol Eng"},{"issue":"14","key":"4915_CR14","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.66.14.53","volume":"66","author":"KY Chen","year":"2025","unstructured":"Chen KY, Chan HC, Chan CM. Can immune checkpoint modulation redefine ocular immunotherapy? Emerging mechanisms, challenges, and translational opportunities-a comprehensive review. Invest Ophthalmol Vis Sci. 2025;66(14):53. https:\/\/doi.org\/10.1167\/iovs.66.14.53.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4915_CR15","first-page":"859","volume-title":"Mayo clinic proceedings","author":"T O\u2019Brien","year":"2009","unstructured":"O\u2019Brien T, Barry FP. Stem cell therapy and regenerative medicine. In: Mayo clinic proceedings, vol. 84. Amsterdam: Elsevier; 2009. p. 859\u201361."},{"issue":"5","key":"4915_CR16","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.3390\/ijms23052850","volume":"23","author":"M Mousaei Ghasroldasht","year":"2022","unstructured":"Mousaei Ghasroldasht M, Seok J, Park H-S, Liakath Ali FB, Al-Hendy A. Stem cell therapy: from idea to clinical practice. Int J Mol Sci. 2022;23(5):2850.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4915_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1091\/mbc.e02-06-0353","volume":"14","author":"X Wu","year":"2003","unstructured":"Wu X, Zhao X, Puertollano R, Bonifacino JS, Eisenberg E, Greene LE. Adaptor and clathrin exchange at the plasma membrane and trans-Golgi network. Mol Biol Cell. 2003;14(2):516\u201328.","journal-title":"Mol Biol Cell"},{"key":"4915_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fphar.2016.00231","volume":"7","author":"A Marote","year":"2016","unstructured":"Marote A, Teixeira FG, Mendes-Pinheiro B, Salgado AJ. MSCs-derived exosomes: cell-secreted nanovesicles with regenerative potential. Front Pharmacol. 2016;7:231.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4915_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2025.114616","volume":"450","author":"S Chattopadhyay","year":"2025","unstructured":"Chattopadhyay S, et al. Mesenchymal stem cell-derived exosomes: a paradigm shift in clinical therapeutics. Exp Cell Res. 2025;450(1):114616. https:\/\/doi.org\/10.1016\/j.yexcr.2025.114616.","journal-title":"Exp Cell Res"},{"key":"4915_CR20","doi-asserted-by":"publisher","first-page":"096368972211338","DOI":"10.1177\/09636897221133818","volume":"31","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Lin S, Gao Y. Mesenchymal Stromal Cell\u2013Based therapy for dry eye: current status and future perspectives. Cell Transplant. 2022;31:09636897221133818. https:\/\/doi.org\/10.1177\/09636897221133818.","journal-title":"Cell Transplant"},{"key":"4915_CR21","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.2147\/opth.S322079","volume":"15","author":"SW Rush","year":"2021","unstructured":"Rush SW, Chain J, Das H. Corneal epithelial stem cell supernatant in the treatment of severe dry eye disease: a pilot study. Clin Ophthalmol. 2021;15:3097\u2013107. https:\/\/doi.org\/10.2147\/opth.S322079.","journal-title":"Clin Ophthalmol"},{"key":"4915_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jtos.2020.11.013","volume":"19","author":"M M\u00f8ller-Hansen","year":"2021","unstructured":"M\u00f8ller-Hansen M, et al. Safety and feasibility of mesenchymal stem cell therapy in patients with aqueous deficient dry eye disease. Ocul Surf. 2021;19:43\u201352.","journal-title":"Ocul Surf"},{"key":"4915_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jtos.2023.11.007","volume":"31","author":"M M\u00f8ller-Hansen","year":"2024","unstructured":"M\u00f8ller-Hansen M, et al. Allogeneic mesenchymal stem cell therapy for dry eye disease in patients with Sj\u00f6gren\u2019s syndrome: a randomized clinical trial. Ocul Surf. 2024;31:1\u20138. https:\/\/doi.org\/10.1016\/j.jtos.2023.11.007.","journal-title":"Ocul Surf"},{"issue":"12","key":"4915_CR24","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1038\/mt.2012.208","volume":"20","author":"J Weng","year":"2012","unstructured":"Weng J, et al. Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease. Mol Ther. 2012;20(12):2347\u201354.","journal-title":"Mol Ther"},{"issue":"1","key":"4915_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-025-04292-8","volume":"16","author":"D Zhang","year":"2025","unstructured":"Zhang D, et al. A first-in-human, prospective pilot trial of umbilical cord-derived mesenchymal stem cell eye drops therapy for patients with refractory non-Sj\u00f6gren\u2019s and Sj\u00f6gren\u2019s syndrome dry eye disease. Stem Cell Res Ther. 2025;16(1):202. https:\/\/doi.org\/10.1186\/s13287-025-04292-8.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4915_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-025-04078-9","volume":"25","author":"A Habibi","year":"2025","unstructured":"Habibi A, Khosravi A, Soleimani M, Nejabat M, Dara M, Azarpira N. Efficacy of topical mesenchymal stem cell exosome in Sj\u00f6gren\u2019s syndrome-related dry eye: a randomized clinical trial. BMC Ophthalmol. 2025;25(1):299. https:\/\/doi.org\/10.1186\/s12886-025-04078-9.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"4915_CR27","volume":"2014","author":"E Beyazy\u0131ld\u0131z","year":"2014","unstructured":"Beyazy\u0131ld\u0131z E, et al. 2014 Efficacy of topical mesenchymal stem cell therapy in the treatment of experimental dry eye syndrome model. Stem Cells Int. 2014;2014(1): 250230.","journal-title":"Stem Cells Int"},{"issue":"1","key":"4915_CR28","first-page":"3134543","volume":"2017","author":"HS Aluri","year":"2017","unstructured":"Aluri HS, et al. Delivery of bone Marrow-Derived mesenchymal stem cells improves tear production in a mouse model of Sj\u00f6gren\u2019s syndrome. Stem Cells Int. 2017;2017(1):3134543.","journal-title":"Stem Cells Int"},{"issue":"1","key":"4915_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/mt.2014.159","volume":"23","author":"MJ Lee","year":"2015","unstructured":"Lee MJ, et al. Mesenchymal stem\/stromal cells protect the ocular surface by suppressing inflammation in an experimental dry eye. Mol Ther. 2015;23(1):139\u201346.","journal-title":"Mol Ther"},{"issue":"1","key":"4915_CR30","first-page":"527926","volume":"2015","author":"AJ Villatoro","year":"2015","unstructured":"Villatoro AJ, Fern\u00e1ndez V, Claros S, Rico-Llanos GA, Becerra J, Andrades JA. Use of adipose-derived mesenchymal stem cells in keratoconjunctivitis sicca in a canine model. BioMed Res Int. 2015;2015(1):527926.","journal-title":"BioMed Res Int"},{"issue":"3","key":"4915_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3727\/215517916X693366","volume":"8","author":"MK Bittencourt","year":"2016","unstructured":"Bittencourt MK, et al. Allogeneic mesenchymal stem cell transplantation in dogs with keratoconjunctivitis sicca. Cell Med. 2016;8(3):63\u201377.","journal-title":"Cell Med"},{"issue":"1","key":"4915_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12917-022-03303-7","volume":"18","author":"L-N Wei","year":"2022","unstructured":"Wei L-N, Wu C-H, Lin C-T, Liu I-H. Topical applications of allogeneic adipose-derived mesenchymal stem cells ameliorate the canine keratoconjunctivitis sicca. BMC Vet Res. 2022;18(1):217.","journal-title":"BMC Vet Res"},{"issue":"24","key":"4915_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10245981","volume":"10","author":"M Hermida-Prieto","year":"2021","unstructured":"Hermida-Prieto M, Garc\u00eda-Castro J, Mari\u00f1as-Pardo L. Systemic treatment of immune-mediated keratoconjunctivitis sicca with allogeneic stem cells improves the Schirmer tear test score in a canine spontaneous model of disease. J Clin Med. 2021;10(24):5981.","journal-title":"J Clin Med"},{"key":"4915_CR34","unstructured":"Morris LM. Peri-lacrimal gland injection of allogenic adipose-derived mesenchymal stem cells compared to tacrolimus eyedrops in the treatment of canine Keratoconjunctivitis Sicca. University of Pretoria (South Africa); 2024."},{"issue":"4","key":"4915_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s13577-014-0095-x","volume":"27","author":"B Amorin","year":"2014","unstructured":"Amorin B, et al. Mesenchymal stem cell therapy and acute graft-versus-host disease: a review. Hum Cell. 2014;27(4):137\u201350. https:\/\/doi.org\/10.1007\/s13577-014-0095-x.","journal-title":"Hum Cell"},{"key":"4915_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041167","author":"KY Wu","year":"2023","unstructured":"Wu KY, Ahmad H, Lin G, Carbonneau M, Tran SD. Mesenchymal Stem Cell-Derived Exosomes in ophthalmology: a comprehensive review. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15041167.","journal-title":"Pharmaceutics"},{"key":"4915_CR37","doi-asserted-by":"publisher","unstructured":"Li F, Lu J, Shi X, Li D, Zhou T, Jiang T, Wang S. Effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary Sjogren's syndrome. Sci Rep. 2023;13(1):13521. https:\/\/doi.org\/10.1038\/s41598-023-40802-5","DOI":"10.1038\/s41598-023-40802-5"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-04915-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-04915-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-04915-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:20:23Z","timestamp":1781821223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-04915-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4915"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-04915-8","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not involve any new human participants, human data, or human tissue. Therefore, no Institutional Review Board (IRB) or Ethics Committee approval was required, and the Human Ethics and Consent to Participate declarations are not applicable. All procedures were conducted in accordance with the ethical principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This article does not contain any individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"224"}}